

Generics Market Summary, Competitive Analysis and Forecast to 2027 (Global Almanac)

Industry Report | 2023-08-17 | 527 pages | MarketLine

AVAILABLE LICENSES:

- Single user licence (PDF) \$2995.00
- Site License (PDF) \$5990.00
- Enterprisewide license (PDF) \$8985.00

Report description:

Generics Market Summary, Competitive Analysis and Forecast to 2027 (Global Almanac)

Summary

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices.
- Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.
- Regional volumes are calculated as weighted averages of countries that comprise the region where volume data exists.
- All market data and forecasts are represented in nominal terms (i.e., without adjustment for inflation) and all currency conversions used in the creation of this report have been calculated using constant 2022 annual average exchange rates.
- The global generics market had total revenues of \$336.9 billion in 2022, representing a compound annual growth rate (CAGR) of 7.2% between 2017 and 2022.
- Market consumption volume increased with a CAGR of 1.8% between 2017 and 2022, to reach a total of 40.1% in 2022.

- In 2022, the growth of the global generics market decelerated, witnessing an annual growth of 7.2% due to the reduction in generic drug prices.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the global generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market
- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume

Reasons to Buy

- What was the size of the global generics market by value in 2022?
- What will be the size of the global generics market in 2027?
- What factors are affecting the strength of competition in the global generics market?
- How has the market performed over the last five years?
- How large is the global generics market in relation to its regional counterparts?

Table of Contents:

Table of Contents

- 1 EXECUTIVE SUMMARY
- 1.1. Market value
- 1.2. Market value forecast
- 1.3. Market volume
- 1.4. Market volume forecast
- 1.5. Geography segmentation
- 1.6. Competitive landscape
- 2 Introduction
- 2.1. What is this report about?
- 2.2. Who is the target reader?
- 2.3. How to use this report
- 2.4. Definitions
- 3 Global Generics
- 3.1. Market Overview
- 3.2. Market Data
- 3.3. Market Segmentation
- 3.4. Market outlook
- 3.5. Five forces analysis
- 4 Macroeconomic Indicators
- 4.1. Country data
- 5 Generics in Asia-Pacific
- 5.1. Market Overview
- 5.2. Market Data
- 5.3. Market Segmentation
- 5.4. Market outlook
- 5.5. Five forces analysis

- 6 Generics in Europe
- 6.1. Market Overview
- 6.2. Market Data
- 6.3. Market Segmentation
- 6.4. Market outlook
- 6.5. Five forces analysis
- 7 Macroeconomic Indicators
- 7.1. Country data
- 8 Generics in France
- 8.1. Market Overview
- 8.2. Market Data
- 8.3. Market Segmentation
- 8.4. Market outlook
- 8.5. Five forces analysis
- 9 Macroeconomic Indicators
- 9.1. Country data
- 10 Generics in Germany
- 10.1. Market Overview
- 10.2. Market Data
- 10.3. Market Segmentation
- 10.4. Market outlook
- 10.5. Five forces analysis
- 11 Macroeconomic Indicators
- 11.1. Country data
- 12 Generics in Australia
- 12.1. Market Overview
- 12.2. Market Data
- 12.3. Market Segmentation
- 12.4. Market outlook
- 12.5. Five forces analysis
- 13 Macroeconomic Indicators
- 13.1. Country data
- 14 Generics in Brazil
- 14.1. Market Overview
- 14.2. Market Data
- 14.3. Market Segmentation
- 14.4. Market outlook
- 14.5. Five forces analysis
- 15 Macroeconomic Indicators
- 15.1. Country data
- 16 Generics in Canada
- 16.1. Market Overview
- 16.2. Market Data
- 16.3. Market Segmentation
- 16.4. Market outlook
- 16.5. Five forces analysis
- 17 Macroeconomic Indicators

- 17.1. Country data
- 18 Generics in China
- 18.1. Market Overview
- 18.2. Market Data
- 18.3. Market Segmentation
- 18.4. Market outlook
- 18.5. Five forces analysis
- 19 Macroeconomic Indicators
- 19.1. Country data
- 20 Generics in India
- 20.1. Market Overview
- 20.2. Market Data
- 20.3. Market Segmentation
- 20.4. Market outlook
- 20.5. Five forces analysis
- 21 Macroeconomic Indicators
- 21.1. Country data
- 22 Generics in Indonesia
- 22.1. Market Overview
- 22.2. Market Data
- 22.3. Market Segmentation
- 22.4. Market outlook
- 22.5. Five forces analysis
- 23 Macroeconomic Indicators
- 23.1. Country data
- 24 Generics in Italy
- 24.1. Market Overview
- 24.2. Market Data
- 24.3. Market Segmentation
- 24.4. Market outlook
- 24.5. Five forces analysis
- 25 Macroeconomic Indicators
- 25.1. Country data
- 26 Generics in Japan
- 26.1. Market Overview
- 26.2. Market Data
- 26.3. Market Segmentation
- 26.4. Market outlook
- 26.5. Five forces analysis
- 27 Macroeconomic Indicators
- 27.1. Country data
- 28 Generics in Mexico
- 28.1. Market Overview
- 28.2. Market Data
- 28.3. Market Segmentation
- 28.4. Market outlook
- 28.5. Five forces analysis

- 29 Macroeconomic Indicators
- 29.1. Country data
- 30 Generics in The Netherlands
- 30.1. Market Overview
- 30.2. Market Data
- 30.3. Market Segmentation
- 30.4. Market outlook
- 30.5. Five forces analysis
- 31 Macroeconomic Indicators
- 31.1. Country data
- 32 Generics in North America
- 32.1. Market Overview
- 32.2. Market Data
- 32.3. Market Segmentation
- 32.4. Market outlook
- 32.5. Five forces analysis
- 33 Generics in Russia
- 33.1. Market Overview
- 33.2. Market Data
- 33.3. Market Segmentation
- 33.4. Market outlook
- 33.5. Five forces analysis
- 34 Macroeconomic Indicators
- 34.1. Country data
- 35 Generics in Scandinavia
- 35.1. Market Overview
- 35.2. Market Data
- 35.3. Market Segmentation
- 35.4. Market outlook
- 35.5. Five forces analysis
- 36 Generics in Singapore
- 36.1. Market Overview
- 36.2. Market Data
- 36.3. Market Segmentation
- 36.4. Market outlook
- 36.5. Five forces analysis
- 37 Macroeconomic Indicators
- 37.1. Country data
- 38 Generics in South Africa
- 38.1. Market Overview
- 38.2. Market Data
- 38.3. Market Segmentation
- 38.4. Market outlook
- 38.5. Five forces analysis
- 39 Macroeconomic Indicators
- 39.1. Country data
- 40 Generics in South Korea

- 40.1. Market Overview
- 40.2. Market Data
- 40.3. Market Segmentation
- 40.4. Market outlook
- 40.5. Five forces analysis
- 41 Macroeconomic Indicators
- 41.1. Country data
- 42 Generics in Spain
- 42.1. Market Overview
- 42.2. Market Data
- 42.3. Market Segmentation
- 42.4. Market outlook
- 42.5. Five forces analysis
- 43 Macroeconomic Indicators
- 43.1. Country data
- 44 Generics in Turkey
- 44.1. Market Overview
- 44.2. Market Data
- 44.3. Market Segmentation
- 44.4. Market outlook
- 44.5. Five forces analysis
- 45 Macroeconomic Indicators
- 45.1. Country data
- 46 Generics in The United Kingdom
- 46.1. Market Overview
- 46.2. Market Data
- 46.3. Market Segmentation
- 46.4. Market outlook
- 46.5. Five forces analysis
- 47 Macroeconomic Indicators
- 47.1. Country data
- 48 Generics in The United States
- 48.1. Market Overview
- 48.2. Market Data
- 48.3. Market Segmentation
- 48.4. Market outlook
- 48.5. Five forces analysis
- 49 Macroeconomic Indicators
- 49.1. Country data
- 50 Company Profiles
- 50.1. Teva Pharmaceutical Industries Limited
- 50.2. Pfizer Inc.
- 50.3. Sun Pharmaceutical Industries Ltd
- 50.4. Viatris Inc.
- 50.5. Sanofi SA
- 50.6. Les Laboratoires Servier
- 50.7. STADA Arzneimittel AG

- 50.8. Novartis AG
- 50.9. Lupin Ltd
- 50.10. Aspen Pharmacare Holdings Ltd
- 50.11. EMS SA
- 50.12. Ache Laboratorios Farmaceuticos SA
- 50.13. Eurofarma Laboratorios SA
- 50.14. Apotex, Inc.
- 50.15. Grand Pharmaceutical Group Limited
- 50.16. Aurobindo Pharma Ltd
- 50.17. Cipla Limited
- 50.18. PT Kalbe Farma Tbk
- 50.19. PT Sanbe Farma
- 50.20. PT Soho Global Health Tbk
- 50.21. PT Indofarma (Persero), Tbk
- 50.22. Daiichi Sankyo Co Ltd
- 50.23. Sawai Pharmaceutical Co Ltd
- 50.24. Krka, d. d., Novo mesto
- 50.25. Abbott Laboratories
- 50.26. Adcock Ingram Holdings Ltd
- 50.27. Yuhan Corp
- 50.28. Esteve Group
- 50.29. Deva Holding AS
- 50.30. Nobelpharma Co Ltd
- 50.31. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
- 51 Appendix
- 51.1. Methodology
- 51.2. About MarketLine



Generics Market Summary, Competitive Analysis and Forecast to 2027 (Global Almanac)

Industry Report | 2023-08-17 | 527 pages | MarketLine

Print this form		
_		
☐ - Complete the re	elevant blank fields and sign	
Send as a scann	ned email to support@scotts-international.com	
ORDER FORM:		
Select license	License	Price
	Single user licence (PDF)	\$2995.00
	Site License (PDF)	\$5990.00
	Enterprisewide license (PDF)	\$8985.00
	VAT	
	Total	
*Dlagge circle the relevan	ant licence ention. For any questions places contact support@coatte international com or 0049 602.3	204.246
	ant license option. For any questions please contact support@scotts-international.com or 0048 603 3 at 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone*	
** VAT will be added a	t 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone*	
Email* First Name*	t 23% for Polish based companies, individuals and EU based companies who are unable to provide a	
** VAT will be added a	t 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone*	
Email* First Name*	t 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone*	
Email* First Name* Job title*	Phone* Last Name*	
Email* First Name* Job title* Company Name*	Phone* Last Name* EU Vat / Tax ID / NIP number*	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Signature